JPRN-UMIN000046211已完成未知
Efficacy and Safety of the third dose of mRNA COVID-19 Vaccine in healthy volunteers: An observational study. - mRNA vaccine third dose study in healthy volunteers
Kobe City Medical Center General Hospital, Department of Hematology0 个研究点目标入组 30 人开始时间: 2021年11月28日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Those that the principal investigator or sub-investigator deems inappropriate for participation in the study 2) Patients with a history or coexistence of immunosuppressive medication, autoimmune diseases (systemic lupus erythematosus, Sjogren's syndrome, dermatomyositis/polymyositis, mixed connective tissue disease, systemic scleroderma, rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, spondyloarthritis and related diseases, vasculitis syndrome, inflammatory bowel disease, Guillain-Barre syndrome, multiple sclerosis, neuromyelitis optica) Multiple sclerosis, neuromyelitis optica). 3) Patients with a history of COVID-19 4) Patients who are unable to communicate with others
研究者
相似试验
已完成
不适用
Efficacy and Safety of the fourth dose of mRNA COVID-19 Vaccine in healthy volunteers: An observational study.JPRN-UMIN000048653Kobe City Medical Center General Hospital10
招募中
2 期
Immunogenicity and safety of the third dose COVID-19 vaccine in Thai population.After the third dose of the COVID-19 vaccine, the immune response in healthy volunteers who received 2 doses of COVID19 vaccine (CoronaVac or ChAdOx1) at least three months.COVID-19 vaccine, Third dose, ChAdOx1, coronavac, Sinovac, BNT162b2, SinopharmTCTR20210731004Chulabhorn Royal Academy5,520
招募中
2 期
Immunogenicity and safety of the third dose COVID-19 vaccine via intradermal compare with intramuscular administration (Randomized controlled trial)The immune response after the third dose of the COVID-19 vaccine via intradermal administration in healthy volunteers.COVID-19 vaccine, Third dose, intradermal, ChAdOx1, coronavac, Sinovac, BNT162b2, mRNA1263, SinopharmTCTR20210731003Chulabhorn Royal Academy960
进行中（未招募）
1 期
Assessment of effectiveness and safety of a 3rd dose of mRNA vaccine in kidney transplant recipients.SARS-CoV-2 infection in kidney transplant recipientssafety, effectiveness and immunogenicity of 3rd dose of SARS-CoV-2 mRNA vaccine.EUCTR2022-000319-30-CZInstitut Klinické a Experimentální Medicíny180
已完成
4 期
Safety and efficacy of the 3rd and the 4th dose of mRNA COVID19 vaccine in kidney transplant recipientsCOVID19 vaccination responseKidney transplant recipientsInfection - Studies of infection and infectious agentsRespiratory - Other respiratory disorders / diseasesACTRN12622001106729Martin Kacer126